Bernard Uitdehaag1, Gisela Kobelt2, Jenny Berg3, Daniela Capsa3, Johan Dalén3. 1. MS Center Amsterdam, Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands. 2. European Health Economics, Mulhouse, France. 3. Mapi Group, Stockholm, Sweden.
Abstract
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015. RESULTS: A total of 382 patients (mean age: 54 years) participated in the Netherlands; 81% were below retirement age and of these, 31% were employed. Employment was inversely related to disease severity, and MS affected productivity at work for 82% of patients. Overall, 96% and 73% of patients experienced fatigue and cognitive difficulties, respectively, as a problem. Mean utility and annual costs were 0.744 and €23,100 at Expanded Disability Status Scale (EDSS) 0-3, 0.595 and €32,300 at EDSS 4-6.5, and 0.297 and €50,500 at EDSS 7-9. The mean cost of a relapse was estimated at €3000. CONCLUSION: This study provides current data on MS in the Netherlands that are important for the development of health policies and to estimate the value of current and future treatments.
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015. RESULTS: A total of 382 patients (mean age: 54 years) participated in the Netherlands; 81% were below retirement age and of these, 31% were employed. Employment was inversely related to disease severity, and MS affected productivity at work for 82% of patients. Overall, 96% and 73% of patients experienced fatigue and cognitive difficulties, respectively, as a problem. Mean utility and annual costs were 0.744 and €23,100 at Expanded Disability Status Scale (EDSS) 0-3, 0.595 and €32,300 at EDSS 4-6.5, and 0.297 and €50,500 at EDSS 7-9. The mean cost of a relapse was estimated at €3000. CONCLUSION: This study provides current data on MS in the Netherlands that are important for the development of health policies and to estimate the value of current and future treatments.
Authors: Dennis A M van Gorp; Karin van der Hiele; Marco A P Heerings; Peter J Jongen; Jac J L van der Klink; Michiel F Reneman; Edo P J Arnoldus; Ernesto A C Beenakker; Jeroen J J van Eijk; Stephan T F M Frequin; Koen de Gans; Elske Hoitsma; Jop P Mostert; Wim I M Verhagen; Désirée Zemel; Leo H Visser; Huub A M Middelkoop Journal: Neurol Sci Date: 2019-07-19 Impact factor: 3.307
Authors: Ingrid E H Kremer; Mickael Hiligsmann; Josh Carlson; Marita Zimmermann; Peter J Jongen; Silvia M A A Evers; Svenja Petersohn; Xavier G L V Pouwels; Nick Bansback Journal: Med Decis Making Date: 2020-11 Impact factor: 2.583